Contineum Therapeutics, Inc. Class A Common Stock(CTNM)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$12.82
After hours $12.82 +0.00%
52-Week Range
$3.69 – $16.33
YTD
+12.55%
IV Rank (30D)
51.22
Straddle Price
$4.95
P/C Vol Ratio
3.67
Market Cap
$0.4B
Fair Value
+33.7% vs price
Confidence: 7% Alpha Score: 0.65

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.46%
Beta vs SPY1.00
Cost of Equity (CAPM)9.96% (VRP-adj)
WACC9.81%
Volatility Risk Premium+143.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-23.4%
Book / Price70.5% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$12.99 (Market Anchor value)
SMA 20 / Bollinger Mid$12.32
Bollinger Width / SMA20192.4% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: BIIB, MRNA, REGN (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$17.14
Current Price
$12.82
Deviation
+33.7%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $17.14 100% median 2.0× · 3 peers
Peer P/S n/a 0% median 4.3× · 3 peers
Market Anchor (SMA50) $12.99 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-24 · updated 2026-06-24 20:45:31.365000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$0.4B

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remit…

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +0.17% 2
Feb -7.31% 2
Mar -3.96% 2
Apr -8.99% 3
May -2.43% 3
Jun -2.16% 3
Jul +24.55% 2
Aug +1.46% 2
Sep +11.08% 2
Oct -4.68% 2
Nov -5.86% 2
Dec +3.14% 2
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $12.29
SMA 50: $12.99
SMA 200: $12.52
Current: $12.98
EMA 12: $12.22
EMA 26: $12.49
MACD: -0.2685 | Signal: 0.0833
BEARISH
ADX (14): 12.43
RANGE
+DI: 16.51
−DI: 16.32
Momentum Oscillators
RSI (14): 54.65
NEUTRAL
Stoch %K: 46.40
Stoch %D: 35.81
Williams %R: -16.01
Volume & Volatility
BB Upper: $13.64
BB Lower: $10.93
NEUTRAL
OBV: 7,328,506
Vol SMA 20: 232,117
Vol ROC: 30.28%
ATR: $0.93
True Range: $1.07
HV 20: 60.0%
HV 30: 60.9%
HV 60: 57.6%

Data Summary
Data Points: 500
Last Updated: 2026-06-24T19:55:29.248000
Date Range: 2024-06-25T00:00:00 – 2026-06-23T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
5 of 5 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-14 Pre-Market 102.24% 1.32% 0.01x Within
2025-08-05 Pre-Market 83.62% 3.45% 0.04x Within
2025-10-30 Pre-Market 50.69% 5.14% 0.10x Within
2026-03-05 Pre-Market 34.14% 7.03% 0.21x Within
2026-05-05 Pre-Market 35.02% 1.17% 0.03x Within
Options Activity
IV Rank (30D)
51.22
IV Rank (7D)
51.22
Avg IV
197.1%
Straddle (30D)
$4.95
Straddle (7D)
$4.95
P/C Volume
3.67
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.74
Correlation (SPY)
11.6%
0.01
Ann. Volatility
78.6%
SPY Volatility
12.5%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 29,762,856 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

89 filers30,490,854 shares$394.67M value102.45% of float
# Filer Shares Value % of Total % of Float Period
1 SUVRETTA CAPITAL MANAGEMENT, LLC 2,841,334 $37.11M 9.40% 9.55% 2026-03-31
2 JANUS HENDERSON GROUP PLC 2,734,836 $35.59M 9.02% 9.19% 2026-03-31
3 JOHNSON & JOHNSON 1,979,173 $25.85M 6.55% 6.65% 2026-03-31
4 FRANKLIN RESOURCES INC Custodian 1,839,227 $24.02M 6.09% 6.18% 2026-03-31
5 BALYASNY ASSET MANAGEMENT L.P. 1,685,635 $22.01M 5.58% 5.66% 2026-03-31
6 MILLENNIUM MANAGEMENT LLC Custodian 1,535,449 $20.05M 5.08% 5.16% 2026-03-31
7 BAKER BROS. ADVISORS LP 1,420,838 $18.56M 4.70% 4.77% 2026-03-31
8 RA CAPITAL MANAGEMENT, L.P. 1,296,012 $16.93M 4.29% 4.35% 2026-03-31
9 PERCEPTIVE ADVISORS LLC 1,255,592 $16.40M 4.15% 4.22% 2026-03-31
10 VANGUARD GROUP INC Custodian 1,270,858 $14.53M 3.68% 4.27% 2025-12-31
11 FMR LLC Custodian 814,871 $10.64M 2.70% 2.74% 2026-03-31
12 Ikarian Capital, LLC 807,874 $10.55M 2.67% 2.71% 2026-03-31
13 GREAT POINT PARTNERS LLC 800,198 $10.45M 2.65% 2.69% 2026-03-31
14 Longaeva Partners L.P. 732,088 $9.56M 2.42% 2.46% 2026-03-31
15 SECTORAL ASSET MANAGEMENT INC 727,587 $9.50M 2.41% 2.44% 2026-03-31
16 HHLR ADVISORS, LTD. 669,337 $8.74M 2.21% 2.25% 2026-03-31
17 BlackRock, Inc. Custodian 669,123 $8.74M 2.21% 2.25% 2026-03-31
18 Red Tree Management, LLC 638,158 $8.33M 2.11% 2.14% 2026-03-31
19 Versant Venture Management, LLC 542,628 $7.09M 1.80% 1.82% 2026-03-31
20 Jones Hill Capital LP 513,053 $6.70M 1.70% 1.72% 2026-03-31
21 Boxer Capital Management, LLC 494,000 $6.45M 1.63% 1.66% 2026-03-31
22 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian 371,636 $4.85M 1.23% 1.25% 2026-03-31
23 CITADEL ADVISORS LLC Custodian 350,200 $4.57M 1.16% 1.18% 2026-03-31
24 GOLDMAN SACHS GROUP INC Custodian 307,108 $4.01M 1.02% 1.03% 2026-03-31
25 SILVERARC CAPITAL MANAGEMENT, LLC 301,729 $3.94M 1.00% 1.01% 2026-03-31
1 filers$147.58K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $147.58K 100.00% 2026-03-31
# Filer Notional Value % of Total Period
Insider Activity
Latest: 2026-06-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-01 Daniel S. Lorrain Chief Scientific Officer Sell (S) −4,170 $13.16 -$54.9K EDGAR
2026-05-01 Daniel S. Lorrain Chief Scientific Officer Sell (S) −4,170 $13.12 -$54.7K EDGAR
2026-04-06 Daniel S. Lorrain Chief Scientific Officer Sell (S) −4,170 $13.43 -$56.0K EDGAR
2026-03-02 Daniel S. Lorrain Chief Scientific Officer Sell (S) −4,170 $15.01 -$62.6K EDGAR
2026-03-02 Tim Watkins CMO & Head of Development Mixed $9.76 -$38.0K EDGAR
2026-02-26 Carmine N. Stengone CEO and President Mixed $8.64 -$104.8K EDGAR
2026-02-26 Daniel S. Lorrain Chief Scientific Officer Mixed $8.52 -$122.0K EDGAR
2026-02-20 Daniel S. Lorrain Chief Scientific Officer Mixed $8.51 -$1.5K EDGAR
2026-02-13 Daniel S. Lorrain Chief Scientific Officer Mixed $8.51 -$6.0K EDGAR
2026-02-13 Carmine N. Stengone CEO and President Mixed $8.63 -$5.9K EDGAR
2026-02-05 Daniel S. Lorrain Chief Scientific Officer Sell (S) −4,170 $14.94 -$62.3K EDGAR
2026-01-30 John Stephen Healy General Counsel and Corp Sec Grant (A) +206,411 opt EDGAR
2026-01-30 Daniel S. Lorrain Chief Scientific Officer Grant (A) +166,500 opt EDGAR
2026-01-30 Peter T Slover Chief Financial Officer Grant (A) +192,000 opt EDGAR
2026-01-30 Tim Watkins CMO & Head of Development Mixed $9.34 -$34.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
4 insiders · @ $12.98
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Versant Ventures IV, LLC 10%+ Owner 767,320 $9.96M $0 1 2024-04-11
2 Daniel S. Lorrain Chief Scientific Officer 149,482 $1.94M -$640.8K 15 2026-06-01
3 Carmine N. Stengone CEO and President 14,954 $194.1K -$120.1K 5 2026-02-26
4 Stephen L. Huhn CMO & Sr VP, Clinical Dev. 12,800 $166.1K $0 3 2025-01-31
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-06-01
Last 30d: 1 filing · $56K notice value  ·  Last 90d: 3 filings · $122K notice value · 1 unique filer · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.

Top 90-day filers: DANIEL LORRAIN (3, $122K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-06-01 DANIEL LORRAIN Officer 4,170 $56.3K 2026-06-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-01 DANIEL LORRAIN Officer 4,170 $53.5K 2026-05-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-06 DANIEL LORRAIN Officer 914 $12.3K 2026-04-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-02-11 DANIEL LORRAIN Officer 16,050 $252.8K 2026-02-11 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-02-11 CARMINE STENGONE Director, Officer 7,500 $118.1K 2026-02-11 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-02-03 DANIEL LORRAIN Officer 4,170 $60.0K 2026-02-03 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-01-05 DANIEL LORRAIN Officer 4,170 $47.5K 2026-01-05 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-12-29 TIMOTHY WATKINS Officer 10,833 $134.4K 2025-12-29 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-12-23 DANIEL LORRAIN Officer 4,170 $51.1K 2025-12-23 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-11-18 DANIEL LORRAIN Officer 26,370 $453.8K 2024-11-18 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio1.7
EV/EBITDA-6.2
TTM Net Income$-0.1B
TTM EPS$-1.95
ROE-23.4%